VIAL: 1 x 50 mg/2 ml. Dosage:
IV use. Dosage has to be adjusted according to the indication, general condition, renal function and concurrent chemotherapy and the blood counts. See prescribing information for full details. Prescribing Restrictions:
Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. For the initial treatment of patients with B-cell chronic lymphocytic leukemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves. Contra-Indications:
Hypersensitivity to fludarabine or to any of the constituents. Patients with impaired renal function and creatinine clearance below 30 ml/min. Patients with decompensated hemolytic anemia. Pregnancy and lactation. See prescribing information for full details. Special Precautions:
See prescribing information for full details. Side Effects:
Myelosuppression (neutropenia, thrombocytopenia and anemia), fever chills and infection including pneumonia. See prescribing information for full details. Drug Interactions:
See prescribing information for full details.